Literature DB >> 1551741

Pharmacokinetics and metabolism of oral diosmin in healthy volunteers.

D Cova1, L De Angelis, F Giavarini, G Palladini, R Perego.   

Abstract

Pharmacokinetic studies of diosmin were performed after an oral administration to healthy volunteers. Diosmin and its aglycone, diosmetin, were determined by HPLC and LC-MS techniques. At least, at the level of sensitivity of our method, no parent compound was present in the plasma but only its aglycone, diosmetin. Analysis of the pharmacokinetic parameters showed that the drug was rapidly absorbed. Diosmetin presents a long plasma elimination half-life ranging from 26 to 43 hours. Our data show the total absence of urinary elimination for both diosmin and its aglycone diosmetin, while its minor metabolites are eliminated in the urine, mainly as glucuronic acid conjugates. The presence of degradation products such as alkyl-phenolic acids confirms a metabolic pattern similar to other flavonoids.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1551741

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  15 in total

Review 1.  Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids.

Authors:  Katherine A Lyseng-Williamson; Caroline M Perry
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 2.  Flavones: Food Sources, Bioavailability, Metabolism, and Bioactivity.

Authors:  Gregory L Hostetler; Robin A Ralston; Steven J Schwartz
Journal:  Adv Nutr       Date:  2017-05-15       Impact factor: 8.701

Review 3.  Pharmacology of Diosmin, a Citrus Flavone Glycoside: An Updated Review.

Authors:  Samar H Gerges; Sara A Wahdan; Doaa A Elsherbiny; Ebtehal El-Demerdash
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-10-23       Impact factor: 2.441

4.  The protective effect of diosmin on hepatic ischemia reperfusion injury: an experimental study.

Authors:  Yusuf Tanrikulu; Mefaret Sahin; Kemal Kismet; Sibel Serin Kilicoglu; Erdinc Devrim; Ceren Sen Tanrikulu; Esra Erdemli; Serap Erel; Kenan Bayraktar; Mehmet Ali Akkus
Journal:  Bosn J Basic Med Sci       Date:  2013-11       Impact factor: 3.363

5.  Diosmin pretreatment affects bioavailability of metronidazole.

Authors:  K Rajnarayana; Mada S Reddy; Devarakonda R Krishna
Journal:  Eur J Clin Pharmacol       Date:  2003-03-01       Impact factor: 2.953

6.  Protein disulfide isomerase inhibitors constitute a new class of antithrombotic agents.

Authors:  Reema Jasuja; Freda H Passam; Daniel R Kennedy; Sarah H Kim; Lotte van Hessem; Lin Lin; Sheryl R Bowley; Sucharit S Joshi; James R Dilks; Bruce Furie; Barbara C Furie; Robert Flaumenhaft
Journal:  J Clin Invest       Date:  2012-05-08       Impact factor: 14.808

7.  Flavonoid-mediated presenilin-1 phosphorylation reduces Alzheimer's disease beta-amyloid production.

Authors:  Kavon Rezai-Zadeh; R Douglas Shytle; Yun Bai; Jun Tian; Huayan Hou; Takashi Mori; Jin Zeng; Demian Obregon; Terrence Town; Jun Tan
Journal:  J Cell Mol Med       Date:  2008-04-09       Impact factor: 5.310

8.  Confirmation of diosmetin 3-O-glucuronide as major metabolite of diosmin in humans, using micro-liquid-chromatography-mass spectrometry and ion mobility mass spectrometry.

Authors:  Luigi Silvestro; Isabela Tarcomnicu; Constanta Dulea; Nageswara Rao B N Attili; Valentin Ciuca; Dan Peru; Simona Rizea Savu
Journal:  Anal Bioanal Chem       Date:  2013-08-16       Impact factor: 4.142

9.  Uncommon serum creatine phosphokinase and lactic dehydrogenase increase during diosmin therapy: two case reports.

Authors:  Giulia Milano; Silvia Leone; Carmen Fucile; Maria Laura Zuccoli; Andrea Stimamiglio; Antonietta Martelli; Francesca Mattioli
Journal:  J Med Case Rep       Date:  2014-06-16

10.  Antihyperalgesic Effect of Hesperidin Improves with Diosmin in Experimental Neuropathic Pain.

Authors:  Azucena I Carballo-Villalobos; María-Eva González-Trujano; Francisco Pellicer; Francisco J López-Muñoz
Journal:  Biomed Res Int       Date:  2016-09-08       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.